Astagraf XL Shortage: What Providers and Prescribers Need to Know in 2026

For transplant nephrologists, transplant surgeons, and clinical pharmacists managing kidney transplant recipients, medication supply issues are a recurring clinical challenge. Astagraf XL (tacrolimus extended-release capsules, Astellas) is the only once-daily tacrolimus capsule formulation FDA-approved for kidney transplant rejection prophylaxis in both adult and pediatric patients who can swallow capsules.

This clinical guide provides the 2026 supply status for Astagraf XL, a review of the tacrolimus shortage history, formulation switching considerations, and patient management protocols when supply is disrupted.

Current Supply Status (2026)

As of 2026, Astagraf XL is not on active FDA shortage. ASHP has confirmed availability of all three strengths (0.5 mg, 1 mg, 5 mg) from Astellas. The ASHP Drug Shortage database lists the following NDC numbers as available: 00469-0647-73 (0.5 mg, 30 count), 00469-0677-73 (1 mg, 30 count), and 00469-0687-73 (5 mg, 30 count).

Clinically relevant caveat: Despite no formal shortage, patients may experience localized stocking difficulties at retail pharmacies. Astagraf XL's specialty-only distribution and brand-only status mean that standard retail pharmacy stocking is inconsistent. Providers should proactively ensure patients are filling through transplant specialty pharmacies.

Tacrolimus Shortage History: Clinical Context

Generic tacrolimus IR capsules have experienced several shortage events, most significantly in 2019 when the American Society of Transplantation and Transplant Pharmacy COPs issued formal guidance. In that shortage, branded formulations including Astagraf XL were recommended as alternatives for patients unable to obtain their generic tacrolimus IR formulation.

Ongoing risks for supply disruption include: concentrated API (active pharmaceutical ingredient) sourcing, complex multi-step manufacturing, allocation-based distribution during demand spikes, and the narrow therapeutic index requiring precise formulation-specific dosing.

Critical Non-Interchangeability Considerations

The most important clinical consideration when Astagraf XL supply is disrupted is the strict non-interchangeability between tacrolimus formulations. The FDA prescribing information explicitly states that Astagraf XL is not interchangeable or substitutable for:

• Tacrolimus immediate-release capsules (Prograf or generic)
• Tacrolimus extended-release tablets (Envarsus XR)
• Tacrolimus for oral suspension

Reported cases outside the U.S. involving inadvertent substitution between tacrolimus immediate-release and extended-release products resulted in graft rejection and other serious adverse reactions. The difference in absorption kinetics between formulations means equivalent milligram doses do not yield equivalent AUC or trough concentrations.

Conversion Protocol If Formulation Switch Is Necessary

If a supervised switch from Astagraf XL to tacrolimus IR becomes clinically necessary:

• The formal 1:1 total daily dose conversion is a starting point, but clinical evidence suggests this may not maintain equivalent trough concentrations in all patients, especially African American recipients who may require approximately 20-30% higher doses of tacrolimus ER
• Measure whole blood trough concentrations at least two times on separate days during the first week after conversion
• Steady state after dose change takes approximately 7 days
• Monitor for signs of under-immunosuppression (rejection) or over-exposure (nephrotoxicity, neurotoxicity)

CYP3A4 Interaction Vigilance During Formulation Transitions

Tacrolimus is primarily metabolized by CYP3A4. When changing formulations, existing CYP3A4 interactions remain critical. Co-administered inhibitors (azole antifungals, HIV protease inhibitors, diltiazem, verapamil, erythromycin) will increase tacrolimus levels; inducers (rifamycins, phenytoin, phenobarbital, carbamazepine, St. John's wort) will decrease them. Any formulation transition should include a comprehensive medication reconciliation to identify new or changing interaction risks.

Patient Communication Guidance

Proactive patient education is critical to preventing medication errors during supply disruptions. Counsel patients to:

• Always verify the appearance and name of dispensed capsules against what they normally receive
• Contact the transplant team immediately if the pharmacy attempts to substitute a different tacrolimus product without explicit provider instruction
• Refill prescriptions 7-10 days early and use specialty pharmacies consistently
• Use medfinder to locate pharmacies with Astagraf XL in stock rather than self-substituting

Clinical Bottom Line for 2026

Astagraf XL is currently available, but the tacrolimus landscape remains dynamic. Providers should direct patients toward specialty pharmacies, encourage early refills, and have a proactive formulation transition plan in place should supply be disrupted. For more on helping your patients access Astagraf XL, see our provider guide to helping patients find Astagraf XL or visit medfinder for providers to learn how medfinder can support your patients.